# Dr Reddy's share price today (Dr Reddys Laboratories Ltd, NSE: DRREDDY)

> Dr Reddy's share price today: ₹1,368.30 at the NSE close on 3 November 2026, up 14.3% in a year. Dr Reddys Laboratories (NSE: DRREDDY) is worth ₹1,14,210 crore, trades at a P/E of 40.8 and has closed between ₹1,148.10 and ₹1,374.10 over the past 52 weeks. > Dr Reddys Laboratories Ltd's share price has risen faster than its earnings: +14.3% in a year, against −25.8% for earnings per share. DRREDDY · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹1,368.30 (+14.3% in a year)
- P/E: 40.8× (higher than 87% of the last 11 years)
- Revenue (Sep 2026): ₹8,698 Cr (−1.5% on a year ago)
- Profit (Sep 2026): ₹913 Cr (−31.7% on a year ago)
- Operating margin: 20.0% (−3.0 points on a year ago)
- ROCE: 13%, FY26
- ROIC: 6.2%, against a 12.0% cost of capital: −5.8 points

The main question: the share price moved +14.3% in a year while yearly earnings per share moved −25.8%. The difference came from the market paying a higher multiple. ## What is the Dr Reddy's share price today? Dr Reddys Laboratories Ltd's share price was ₹1,368.30 at the close on 3 November 2026. It has been falling for 13 weeks. That is 10.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,148 and ₹1,374, and at that close it sat 97% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 5 weeks in a row. Over the last 11 years the share price moved +110% while the NIFTY 500 moved +249%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Dr Reddy's this quarter? Three changes stood out: foreign funds (FIIs) cut their stake for 10 quarters in a row, indian funds and insurers (DIIs) raised their stake for 10 quarters in a row and profit down on a year earlier for 5 quarters in a row. 1. Foreign funds (FIIs) cut their stake for 10 quarters in a row From 29.1% to 20.3% of the company by the September 2026 quarter. 2. Indian funds and insurers (DIIs) raised their stake for 10 quarters in a row From 18.3% to 31.9% of the company by the September 2026 quarter. 3. Profit down on a year earlier for 5 quarters in a row In the September 2026 quarter profit was ₹913 crore, -31.7% on a year earlier. Why: Profit fell mainly because sales of Lenalidomide, a large North American generic medicine, kept shrinking. Next results: check whether new product launches and the rest of the North American business keep growing enough to make up for falling Lenalidomide sales. From the earnings call on 23 Oct 2026. ## What are Dr Reddy's' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Dr Reddy's reported revenue of ₹8,698 crore, down 1.5% from ₹8,828 crore a year earlier, and a profit of ₹913 crore, down 31.7% from ₹1,337 crore. ### Dr Reddy's results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹8,698 crore | ₹8,828 crore | −1.5% |
| Profit | ₹913 crore | ₹1,337 crore | −31.7% |
| Earnings per share | ₹11.08 | ₹16.14 | −31.4% |
| Operating margin | 20.0% | 23.0% | −3.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Dr Reddy's' management discussed these results on a call held on 23 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Dr Reddy's share price history? Dr Reddy's closed at ₹1,368.30 on 3 November 2026, up 14.3% from ₹1,197.60 a year earlier (31 October 2025) and up 43.5% over five years. Its highest weekly close since March 2016 was ₹1,406.27 on 30 August 2024. ### Dr Reddy's share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,229.50 | +11.3% |
| 1 month ago · 1 Oct 2026 | ₹1,206.20 | +13.4% |
| 6 months ago · 30 Apr 2026 | ₹1,322.90 | +3.4% |
| 1 year ago · 31 Oct 2025 | ₹1,197.60 | +14.3% |
| 3 years ago · 3 Nov 2023 | ₹1,052.61 | +30.0% |
| 5 years ago · 4 Nov 2021 | ₹953.23 | +43.5% |
| 10 years ago · 4 Nov 2016 | ₹615.94 | +122.1% |
| Earliest weekly close in our records · 4 Mar 2016 | ₹650.55 | +110.3% |
| Highest weekly close since March 2016 · 30 Aug 2024 | ₹1,406.27 | −2.7% |
| Lowest weekly close since March 2016 · 1 Jun 2018 | ₹388.28 | +252.4% |
| 52-week high (weekly close) · 3 Jul 2026 | ₹1,374.10 | −0.4% |
| 52-week low (weekly close) · 31 Jul 2026 | ₹1,148.10 | +19.2% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (564 weekly closes from 4 March 2016 to 3 November 2026.)

## What is the latest news on Dr Reddy's? 3 Nov 2026: Dr Reddy's closed at ₹1,368.30, up 11.3% on the week and up 13.4% on the month. 23 Oct 2026: Dr Reddy's held its results call for July to September 2026. Management guided: Semaglutide relaunch in November 2026 after validation; FY27 delivery 6-7 million pens, tentative 12-15 million run-rate estimate and 89-market goal. ### Earlier

- Results for July to September 2026: Revenue down 1.5% and profit down 31.7% on a year earlier. - 10 Jul 2026: ex-date for a dividend of ₹8 a share. - 28 Oct 2024: Share split: face value cut from ₹5 to ₹1 a share (ex-date). ## What dividend does Dr Reddy's pay? Dr Reddy's paid ₹8 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.58% at the ₹1,368.30 close on 3 November 2026. The last was a dividend of ₹8 a share, ex-date 10 July 2026. ### Dr Reddy's dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 10 Jul 2026 | ₹8 | Dividend |
| 10 Jul 2025 | ₹8 | Dividend |
| 16 Jul 2024 | ₹40 | Dividend |
| 11 Jul 2023 | ₹40 | Dividend |
| 11 Jul 2022 | ₹30 | Dividend |
| 9 Jul 2021 | ₹25 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Dr Reddys Laboratories Ltd paid out 16% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Dr Reddy's management say on the latest results call? On the call for July to September 2026, held on 23 October 2026, Dr Reddy's' management guided: Semaglutide relaunch in November 2026 after validation; FY27 delivery 6-7 million pens, tentative 12-15 million run-rate estimate and 89-market goal. > “Subject to successful validation, we expect to relaunch Semaglutide directly as well as through our partners in November 2026, consistent with the timelines communicated earlier.”
> Erez Israeli, on the call for July to September 2026

### What management guided

- Gross margin 50-55%; operating profit 20%+ sustainable, aiming for 25% and 21%+ with successful semaglutide. - SG&A around 32% for the rest of FY27; R&D 7-8% in coming quarters; war-related KSM, solvent and freight drag around 100 basis points of operating profit through Q3-Q4. - SC filing around February-March 2027, US SC January to March 2028 and non-US IV/SC April to June 2027; potential hundreds of millions of dollars. - FY27 capital spending ₹1,600-1,700 crore. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/87-23-Oct-2026.pdf). (From the call for July to September 2026, 23 October 2026.)

## What to watch in Dr Reddy's' next results? When Dr Reddy's reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Semaglutide drug-product validation and partner supply; check relaunch timing and availability in the stated launch markets. - What to check (from the call)
- Semaglutide drug-product validation and partner supply; check relaunch timing and availability in the stated launch markets. - Abatacept EIR and FDA decision; track approval versus CRL and readiness for formulary onboarding. - Complex injectables move from pipeline to FDA approvals and launches; check whether product specifics and approvals emerge. - NRT transition: test whether the profitability advantage persists as reported sales comparisons normalize. ## Which stock lists is Dr Reddy's on? Dr Reddy's is on 5 of our India lists: Momentum stocks, Breakout stocks, Nifty 50 companies, 52 week high & low and Pharma stocks. - [Momentum stocks Market cap cr: 112014.31804733728](https://www.sectoralpha.in/momentum-stocks-india)
- [Breakout stocks Breakout date: 30 October 2026](https://www.sectoralpha.in/breakout-stocks-india)
- [Nifty 50 companies](https://www.sectoralpha.in/nifty-50-stocks-list)
- [52 week high & low 52-week position: Near 52-week high](https://www.sectoralpha.in/52-week-high-stocks-india)
- [Pharma stocks Market value (₹ crore): 112014.31804733728](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Dr Reddy's profitable? Dr Reddys Laboratories Ltd earned ₹913 Cr of net profit in the Sep 2026 quarter, −31.7% on the same quarter a year earlier. Full-year FY26 profit was ₹4,158 Cr. Over 10 years profit has grown 6.9% a year on average. That is 10.5% of the quarter's revenue. The same quarter a year earlier earned ₹1,337 Cr. For the full year, FY26 profit was ₹4,158 Cr (−27.4% on the year before). Why profit moved: revenue changed −1.5% on a year earlier and the margin moved −3.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −50.5% and revenue −3.5%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Dr Reddy's make, and is it growing? Dr Reddys Laboratories Ltd reported ₹8,698 Cr of revenue in the Sep 2026 quarter, −1.5% on the same quarter a year earlier. Over 10 years it has grown 8.0% a year on average. The last full year, FY26, came in at ₹33,700 Cr. The last four reported quarters add to ₹33,097 Cr. Why this happened. Semaglutide is the single most important new revenue driver for the next 3 years. Health Canada approval for injectable semaglutide gives Dr Reddy's first-mover advantage in a market where the originator (Novo Nordisk) commands premium pricing. India launched as Obeda on November 2025 patent expiry. The near-term geometry: 6 to 7 million units by end CY26 (across approved + about-to-approve markets), ramping to 12M in FY27, with potential 40M+ per year upon FTO-11 qualification in FY28. Pricing: list price ~50% of Novo, net realization $25 to 30/unit in most markets (higher in premium geographies). Brazil remains a near-term risk (ANVISA review, 3 to 4 month delay confirmed) but management retains…

FY26 revenue was ₹33,700 Cr, +3.2% on the year before. Recent pace: the last four quarters grew −3.5% on average, against 8.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −3.5%, against +4.9% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −51.9%, against −28.7% a year (rolling over). ## How much of every ₹100 of sales does Dr Reddy's keep? Dr Reddys Laboratories Ltd's operating margin was 20.0% in the Sep 2026 quarter, 3.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 14.0% and 28.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −3.0 percentage points on the year while gross margin changed −1.0 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Dr Reddy's' profit turning into cash? Over the last 3 years, 96% of Dr Reddys Laboratories Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹5,674 Cr of operating cash against ₹4,158 Cr of profit. After ₹4,890 Cr of spending on assets, ₹784 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 96% of profit came in as cash: the cash cycle got 12 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 3.5× depreciation over three years. The next section checks what that spending is building. ## Where does Dr Reddy's' cash go? Dr Reddys Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 247 days in FY26, down from 259 days in FY21. It spent ₹18,507 Cr on assets over the last 3 years. Customers take 110 days to pay, and stock sits for 228 days on average. At FY26 sales of ₹33,700 Cr, each day of that cycle ties up about ₹92.3 Cr, so roughly ₹22,805 Cr is tied up in the business at any time. FY26: customers took 110 days to pay and stock sat for 228 days, about 7.5 months of sales sitting as stock, for a full cycle of 247 days, shorter than FY21's 259. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 228 days. Customers pay about 110 days after that. Suppliers are paid at 91 days. Together that makes the 247-day cycle. Spending on assets: ₹18,507 Cr over the last 3 years, against ₹5,233 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹1,460 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Dr Reddy's' P/E ratio, and how does it compare with its own history? Dr Reddys Laboratories Ltd's P/E is 40.8×, near the high end of its own history: higher than 87% of past readings. Its usual P/E (the middle reading) is 26.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −25.8% while the price moved +14.3%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +7.5% a year; about +7.3% a year came from earnings growth and about +0.2 percentage points from the multiple (roughly no change); over 10 years the price moved +8.3% a year; about +9.0% a year came from earnings growth and about −0.7 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Dr Reddy's business getting better or worse? Dr Reddys Laboratories Ltd's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −3.5% in the latest quarter, against +16.5% at its best in 12 quarters, with ROCE falling at 9.8%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## What is the Dr Reddy's story, and has it been checked? Dr Reddys Laboratories Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: CYCLE BOTTOM TO RECOVERY. Our read, 17 May 2026. Lenalidomide cliff absorbed in Q4, the next earnings base is clean and three converging catalysts (Semaglutide scale, Abatacept US launch, India +16%) are now the story. From the numbers. CYCLE BOTTOM classification with INFLECTION UP yoy trend. Currently in a trough…

From the price. Price stage 4, week 13, above its 200-day line, relative strength rising. From the research. Lenalidomide cliff absorbed in Q4, the next earnings base is clean and three converging catalysts (Semaglutide scale, Abatacept US launch, India +16%) are now the story. Where they disagree. CYCLE BOTTOM classification with INFLECTION UP yoy trend. Currently in a trough driven by Lenalidomide transition earnings compression, not structural business deterioration. What is proven. Lenalidomide cliff absorbed in Q4, the next earnings base is clean and three converging catalysts (Semaglutide scale, Abatacept US launch, India +16%) are now the story. What is not proven yet. Management already walked back 12M pen certainty to 10 to 11M, then 6 to 7M by end CY26. Brazil ANVISA delay adds uncertainty. If net pricing compresses below $25/unit on competitive intensity, PAT contribution thins materially. The test written in advance. Semaglutide volume/margin delivery misses FY27 goals. Measured by: Semaglutide volume/margin delivery misses FY27 goals Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6 to 7M goal; gross margin per unit disclosure by the next result. The test written in advance. Abatacept FDA timeline slips further / Bachupally inspection fails. Measured by: Abatacept FDA timeline slips further / Bachupally inspection fails FDA inspection announcement for Bachupally facility; any Form 483 disclosure in Q1 FY27 concall by the next result. The test written in advance. Management consistency pattern, guidance credibility erosion. Measured by: Management consistency pattern, guidance credibility erosion Q1 FY27 actual NA revenue vs 'double-digit ex-Lena' commitment; Semaglutide actual unit delivery vs 6 to 7M goal by the next result. What the company does. Q4 FY26 was peak pain: adjusted EBITDA held at 19.5% margin despite a Rs 453 Cr shelf-stock adjustment from the Lenalidomide cliff, underlying base business grew double digits throughout. Management credibility is mixed, four documented consistency failures, but the structural thesis (Lenalidomide was finite; biosimilar/GLP-1 pipeline is not) is unchanged and measurable. Lever 11 · More business from existing customers: building. Canada first-mover approval secured; Obeda launched in India on patent expiry; 6 to 7M units goal CY26, 12M FY27, 50+ markets within CY26. Net price $25 to 30/unit floor. FY28 capacity 40M+ on FTO-11 qualification. What proves it keeps working: Semaglutide (GLP-1) Global Ramp, First-Mover in Canada, India. It stops working if Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6 to 7M goal; gross margin per unit disclosure. Lever 15 · Market-share gains: building. India FY26 +16% (Q4 +20%), IPM outperformance 240 to 300 bps; ranked 9th nationally. 28 new brand launches FY26. Move into HRT segment with Proginova/Cyclo-Proginova acquisition. What proves it keeps working: India Business, Structural Market Share Gains, Innovation Franchise. It stops working if Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6 to 7M goal; gross margin per unit disclosure. Lever 10 · New geographies: building. EM FY26 Rs 6,761 Cr (+23%). Russia +8% YoY constant currency (down 23% QoQ sequential, timing/FX). 49 new products in Q4, 129 full-year. Geographic diversification strategy delivering. What proves it keeps working: Emerging Markets, Volume Growth + Geographic Diversification. It stops working if Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6 to 7M goal; gross margin per unit disclosure. Lever 3 · Management change: building. 27 new product launches planned FY27 including Bosutinib; management committed to double-digit NA ex-Lenalidomide growth for FY27. FTO-2 VAI classification in March 2026 supports commercial readiness. What proves it keeps working: North America Base Business Recovery, 27 New Launches, Bosutinib. It stops working if Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6 to 7M goal; gross margin per unit disclosure. Sources: our stock research file (17 May 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Dr Reddy's management deliver what it promised? What Dr Reddys Laboratories Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. EBITDA Margin Outlook Reduced · 23 October 2026. The Jan 2026 call said that semaglutide should bring margins close to 25%, subject to volume, price and mix. In the Oct 2026 call, management instead described successful semaglutide commercialization as taking margins only to 21% plus, without reconciling this lower near-term outlook with the earlier expectation. Capex Guidance Cut · 23 October 2026. The Jan 2026 call indicated roughly 2,000 crores of capex for the following year. In Oct 2026, management lowered the expectation to 1,600-1,700 crores, a roughly 15%-20% reduction, without identifying a project, capacity, or other reason for the cut. Subcutaneous Abatacept Filing Deferred · 23 October 2026. In Jan 2026, management affirmed that the subcutaneous version was on track to be filed in the United States during that year. In Oct 2026, management moved the submission to February 2027, shifting a previously stated 2026 milestone into a new calendar year without explaining the delay. Biologics Sales Figure Is Not Reconciled · 22 July 2026. The January 2026 call described global biologics sales as about US$100 million, whereas the July 2026 Q1 call described biologics as only 2% of overall sales. Because the latest call reported total quarterly revenue of US$853 million, its statement implies roughly US$17 million for the quarter; management did not explain whether the figures use different periods or definitions, creating a material issue for modeling the biologics business and its break-even profile. Every quote above is taken word for word from the company’s own earnings calls. ## What is Dr Reddy's management's track record? Dr. Reddy's has shown a mixed track record in FY26, struggling to meet its 'mid-teens' revenue growth guidance due to heavy price erosion in the US (gRevlimid) and regulatory delays. In October to December 2025, revenue grew only 4.4% on a year earlier to ₹8,727 crore, missing the double-digit goal. However, management successfully defended profitability, with adjusted operating margin hitting 24.8%, very close to the 25% guided level. While the US business declined 16-18% in recent quarters, the India and Emerging Markets segments outperformed, growing 19% and 32% respectively in October to December 2025. The company remains disciplined on R&D spend (7-8% of sales) and tax rates (~25%), aligning with long-term guidance despite top-line volatility. ### Regulatory and governance record

As of early 2026, Dr. Reddy's Laboratories Ltd maintains a clean regulatory record regarding fraud and scams. A major multi-year investigation by the US SEC and DOJ into allegations of improper payments to healthcare professionals in Ukraine and other markets was officially closed in February and March 2026 with no enforcement action recommended. While the company received several USFDA Form 483s in 2025 and 2026 (e.g., 7 observations at Srikakulam in July 2025 and 5 at Bachupally in September 2025), these are standard procedural observations rather than material penalties or fraud. No SEBI enforcement actions or promoter-level scams were identified in the 2024-2026 period. (Checked 20 April 2026.)

## How much does Dr Reddy's earn on its capital? Dr Reddys Laboratories Ltd earned a ROCE of 13% in FY26. That is up from a low of 8% in FY18. Its return on capital used (ROIC) is 5.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 12.3% net margin and 0.60× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 12.3% net margin × 0.60× asset turnover × 1.49× leverage (assets divided by equity) ≈ 11.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 6.2% − 12.0% = −5.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 6.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 11.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Dr Reddy's have too much debt? Dr Reddys Laboratories Ltd has total debt of ₹7,229 Cr against shareholder equity of ₹38,937 Cr as of Sep 2026, so its debt is 0.19× its equity, which is very little. Year by year, that ratio went from 0.18 in FY22 to 0.20 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Dr Reddy's shareholding pattern? Domestic institutions raised their stake in Dr Reddys Laboratories Ltd by 10.4 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 31.9% of the company. Foreign institutions moved −7.2 points over the same period, to 20.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why this happened. North America was the Lenalidomide story in FY26, down 21% YoY to $1.36 Bn as the high-margin arrangement unwound. Q4 FY26 revenue $251 Mn ex-SSA (down 40% YoY). The base resets Q1 FY27 onwards. Management committed under direct Q&A pressure to double-digit growth in North America ex-Lenalidomide for FY27, a reversal from the single-digit guide issued in January 2026 (this is one of the documented consistency concerns). Portfolio refresh: 27 new product launches planned including Bosutinib. Semaglutide is 'on top' of this base. Q1 FY27 will be the first clean read on whether the base business is actually accelerating. Over the last two years: Domestic institutions: +10.4 points over 8 quarters, to 31.9%; Foreign institutions: −7.2 points over 8 quarters, to 20.3%; Promoters: +0.0 points over 8 quarters, to 26.6%. Why the owners changed: foreign institutions moved −7.2 points and domestic institutions +10.4 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Dr Reddy's from balance-sheet trouble? For Dr Reddys Laboratories Ltd, the Z-score is 5.29. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.29 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Dr Reddy's rank in its industry? 39.4 out of 100, rank 34 of 44 in Pharma - Formulators, with 100% of the evidence available. Dr Reddys Laboratories Ltd scores 39.4 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 34. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 4.3 + 12.3 + 11 + 11.8 = 39.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Dr Reddy's compared with? Dr Reddy's ranks 34 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 39.4 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. Dr Reddys Laboratories Ltd this page DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 4.3/35 · Revenue -3.5% · Profit -51.9% · Operating margin change -3 points · 100% evidence Capital efficiency 12.3/25 · ROCE 13% · Operating margin 20% · 100% evidence Valuation 11.0/20 · P/E 40.3× · PEG 1.15 · 100% evidence Relative strength 11.8/20 · Lead over its industry -10.2% · Lead over NIFTY 500 13.5% · 1 year 12.9% · 100% evidence · 2 of 12 weeks ahead Exact sum: 4.3 + 12.3 + 11 + 11.8 = 39.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Dr Reddy's in size? Dr Reddy's is the 4th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Sun Pharmaceutical Industries, Torrent Pharmaceuticals and Zydus Lifesciences. Just below it: Cipla, Mankind Pharma and Aurobindo Pharma. ### Pharma - Formulators companies close in size

1. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) ₹4,26,530 crore
2. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) ₹1,75,479 crore
3. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ₹1,24,239 crore
4. Dr Reddys Laboratories Ltd ₹1,12,849 crore
5. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) ₹1,11,397 crore
6. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) ₹1,02,964 crore
7. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) ₹96,744 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [HDFC Life Insurance Company Ltd](https://www.sectoralpha.in/stocks/hdfc-life-insurance-company-ltd) ₹1,14,039 crore · Finance - Insurance
2. [Bajaj Holdings & Investment Ltd](https://www.sectoralpha.in/stocks/bajaj-holdings-investment-ltd) ₹1,13,705 crore · Finance - Holding Company
3. Dr Reddys Laboratories Ltd ₹1,12,849 crore
4. [LG Electronics India Ltd](https://www.sectoralpha.in/stocks/lg-electronics-india-ltd) ₹1,12,771 crore · Consumer Electronics
5. [Britannia Industries Ltd](https://www.sectoralpha.in/stocks/britannia-industries-ltd) ₹1,11,763 crore · FMCG - Foods

## What else do people ask about Dr Reddy's? ### What is Dr Reddy's's share price today? Dr Reddys Laboratories Ltd's share price is ₹1,368.30, +14.3% over the past year. The whole company is worth ₹1,14,210 Cr on the market. In the last 52 weeks it traded between ₹1,148 to ₹1,374; today it is 97% of the way up from the low, 10.6% above its 200-day average (as of 3 November 2026). ### What were Dr Reddy's's latest quarterly results? Dr Reddys Laboratories Ltd reported revenue of ₹8,698 Cr and net profit of ₹913 Cr for the Sep 2026 quarter. Revenue fell 1.5% and profit fell 31.7% compared with a year earlier. Earnings per share were ₹11.08. The operating margin was 20.0%, 3.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Dr Reddy's's market cap? Dr Reddys Laboratories Ltd's market capitalisation is ₹1,14,210 Cr at a share price of ₹1,368.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Dr Reddy's performing? Dr Reddys Laboratories Ltd's share price has been falling for 13 weeks. In its latest quarter, revenue fell 1.5% and profit fell 31.7% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 5 weeks running (as of 3 November 2026). ### Will Dr Reddy's's share price go up? This page does not forecast Dr Reddys Laboratories Ltd's share price. What it shows instead: the share price is ₹1,368.30, and it has been falling for 13 weeks. Its P/E of 40.8× is higher than 87% of its own last 11 years (as of 3 November 2026). ### Who owns Dr Reddy's? Promoters own 26.6% of Dr Reddys Laboratories Ltd, foreign institutions 20.3%, domestic institutions 31.9% and the public 21.0% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 10.4 percentage points over 8 quarters (as of 3 November 2026). ### Does Dr Reddy's have too much debt? No, Dr Reddys Laboratories Ltd has little debt: its debt is 0.20× its equity, and its operating profit is 17 times its interest bill. FY26 borrowings were ₹7,734 Cr against equity of ₹37,892 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Dr Reddy's in its business cycle? Dr Reddys Laboratories Ltd's FY26 operating margin was 19.0%, against a 13-year range of 14.0% to 28.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 20.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Dr Reddy's story? The main question: the share price moved +14.3% in a year while yearly earnings per share moved −25.8%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Dr Reddy's a stock worth studying right now? What the numbers show: Dr Reddys Laboratories Ltd's share price has risen faster than its earnings: +14.3% in a year, against −25.8% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Dr Reddy's share price forecast for 2026? What management itself guided: Semaglutide relaunch in November 2026 after validation; FY27 delivery 6-7 million pens, tentative 12-15 million run-rate estimate and 89-market goal. ### Where does this page get Dr Reddy's' management information? From Dr Reddy's' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Breakout stocks: https://www.sectoralpha.in/breakout-stocks-india
- Nifty 50 companies: https://www.sectoralpha.in/nifty-50-stocks-list
- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.